Limb Susan L, Brown Kathryn C, Wood Robert A, Wise Robert A, Eggleston Peyton A, Tonascia James, Adkinson N Franklin
Division of Allergy and Clinical Immunology, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA.
J Allergy Clin Immunol. 2005 Dec;116(6):1213-9. doi: 10.1016/j.jaci.2005.09.024. Epub 2005 Nov 2.
Asthma, traditionally characterized as reversible airway obstruction, might lead to structural changes and permanent impairment.
We sought to study the frequency, severity, and reversibility of pulmonary deficits in adults with a history of moderate-to-severe childhood allergic asthma.
Subjects (n = 121) previously enrolled in a randomized trial of immunotherapy for childhood asthma were recalled. Eighty-four young adults (age, 17-30 years; 78% male) were reevaluated by means of spirometry. Subjects with a postbronchodilator FEV1, forced vital capacity, or FEV1/forced vital capacity ratio less than or equal to the 5th percentile or 2 or more indices less than or equal to the 10th percentile (National Health and Nutrition Examination Survey III normative data) were invited to undergo complete pulmonary function testing, physical examination, and chest radiography after 1 week of 1 mg/kg daily prednisone.
Of 84 subjects reevaluated, 40 (48%) had one or more spirometric indices less than or equal to the 5th and 10th percentiles (P < .0001). Twenty-eight of the 40 subjects were reassessed after prednisone treatment, of whom 21 (75%) did not improve. Adult and childhood (age 5-12 years) spirometric results were positively correlated (r = 0.49-0.72, P < .001). Abnormal adult spirometric results were associated with a longer duration of asthma at enrollment in the original trial (4.6 vs 6 years, P=.02), increased childhood methacholine sensitivity (PC20, 0.11 vs 0.18 mg/mL; P = .01), and birth prematurity (adjusted odds ratio, 10.7; 95% CI, 1.4-84.5). Immunotherapy status was unrelated to adult lung function.
Many adults with a history of moderate-to-severe allergic asthma in childhood have irreversible lung function deficits. Childhood spirometry, duration of asthma, methacholine sensitivity, and birth prematurity might identify such individuals at a young age.
哮喘传统上被定义为可逆性气道阻塞,但可能导致结构改变和永久性损害。
我们试图研究有中度至重度儿童过敏性哮喘病史的成年人肺部功能缺陷的频率、严重程度和可逆性。
召回先前参加过儿童哮喘免疫疗法随机试验的受试者(n = 121)。对84名年轻成年人(年龄17 - 30岁;78%为男性)进行肺量计重新评估。支气管扩张剂后第一秒用力呼气容积(FEV1)、用力肺活量或FEV1/用力肺活量比值小于或等于第5百分位数,或2项或更多指标小于或等于第10百分位数(美国国家健康与营养检查调查III标准数据)的受试者,在每日服用1 mg/kg泼尼松1周后,被邀请接受完整的肺功能测试、体格检查和胸部X线检查。
在重新评估的84名受试者中,40名(48%)有一项或多项肺量计指标小于或等于第5和第10百分位数(P <.0001)。40名受试者中的28名在泼尼松治疗后重新评估,其中21名(75%)没有改善。成人和儿童期(5 - 12岁)肺量计结果呈正相关(r = 0.49 - 0.72,P <.001)。成人肺量计异常结果与原试验入组时哮喘持续时间较长(4.6年对6年,P =.02)、儿童期对乙酰甲胆碱敏感性增加(PC20,0.11对0.18 mg/mL;P =.01)以及早产有关(校正比值比,10.7;95%可信区间,1.4 - 84.5)。免疫疗法状态与成人肺功能无关。
许多有中度至重度儿童过敏性哮喘病史的成年人存在不可逆的肺功能缺陷。儿童期肺量计检查、哮喘持续时间、对乙酰甲胆碱敏感性和早产可能有助于在年轻时识别这类个体。